NO20050294L - New compounds useful in the treatment of obesity, type II diabetes and CNS disorders - Google Patents

New compounds useful in the treatment of obesity, type II diabetes and CNS disorders

Info

Publication number
NO20050294L
NO20050294L NO20050294A NO20050294A NO20050294L NO 20050294 L NO20050294 L NO 20050294L NO 20050294 A NO20050294 A NO 20050294A NO 20050294 A NO20050294 A NO 20050294A NO 20050294 L NO20050294 L NO 20050294L
Authority
NO
Norway
Prior art keywords
obesity
diabetes
treatment
type
cns disorders
Prior art date
Application number
NO20050294A
Other languages
Norwegian (no)
Inventor
Gary Johansson
Annika Jenmalm-Jensen
Katarina Beierlein
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0201925A external-priority patent/SE0201925D0/en
Priority claimed from SE0202181A external-priority patent/SE0202181D0/en
Priority claimed from SE0202908A external-priority patent/SE0202908D0/en
Priority claimed from SE0300357A external-priority patent/SE0300357D0/en
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of NO20050294L publication Critical patent/NO20050294L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Foreliggende oppfinnelse angår oppfinnelser med generell formel (1), hvori P er sulfon eller sulfonamid; og A, B, W, X, Y og R 3 er som definert i beskrivelsen; farmasøytiske sammensetninger innbefattende disse forbindelsene og anvendelsen av sammensetningene for profylakse og behandling av medisinske tilstander relatert til fedme, type II diabetes og/eller CNS-forstyrrelser, for å oppnå reduksjon av kroppsvekt og kroppsvektøkning.The present invention relates to inventions of general formula (1) wherein P is sulfone or sulfonamide; and A, B, W, X, Y and R 3 are as defined in the specification; pharmaceutical compositions including these compounds and the use of the compositions for prophylaxis and treatment of medical conditions related to obesity, type II diabetes and / or CNS disorders, to achieve body weight reduction and body weight gain.

NO20050294A 2002-06-20 2005-01-19 New compounds useful in the treatment of obesity, type II diabetes and CNS disorders NO20050294L (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
SE0201925A SE0201925D0 (en) 2002-06-20 2002-06-20 New compounds
SE0202181A SE0202181D0 (en) 2002-07-11 2002-07-11 New compounds
US40612002P 2002-08-26 2002-08-26
SE0202908A SE0202908D0 (en) 2002-10-01 2002-10-01 New compounds
US43401002P 2002-12-17 2002-12-17
SE0300357A SE0300357D0 (en) 2003-02-10 2003-02-10 New compounds
US46470103P 2003-04-23 2003-04-23
PCT/SE2003/001061 WO2004000828A1 (en) 2002-06-20 2003-06-19 New compounds useful for the treatment of obesity, type ii diabetes and cns disorders

Publications (1)

Publication Number Publication Date
NO20050294L true NO20050294L (en) 2005-02-04

Family

ID=30004107

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050294A NO20050294L (en) 2002-06-20 2005-01-19 New compounds useful in the treatment of obesity, type II diabetes and CNS disorders

Country Status (13)

Country Link
EP (1) EP1513828A1 (en)
CN (1) CN1662521A (en)
AU (1) AU2003243091A1 (en)
BR (1) BR0311952A (en)
CA (1) CA2486989A1 (en)
EA (2) EA008835B1 (en)
IL (1) IL165051A0 (en)
MX (1) MXPA04012914A (en)
NO (1) NO20050294L (en)
NZ (3) NZ536600A (en)
RS (1) RS111204A (en)
SG (1) SG156524A1 (en)
WO (1) WO2004000828A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003080580A2 (en) 2002-03-27 2003-10-02 Glaxo Group Limited Quinoline derivatives and their use as 5-ht6 ligands
SE0301446D0 (en) 2003-05-16 2003-05-16 Astrazeneca Ab New Compounds
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
CN1826322B (en) 2003-07-22 2012-04-18 艾尼纳制药公司 Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related therto
SE0302760D0 (en) * 2003-10-20 2003-10-20 Biovitrum Ab New compounds
SE0303480D0 (en) 2003-12-19 2003-12-19 Biovitrum Ab Benzofuranes
EA010298B1 (en) * 2003-12-19 2008-08-29 Биовитрум Аб (Пабл) Novel benzofuran derivatives, which can be used in prophylaxis or treatment of 5-htreceptor-related disorder
GB0407025D0 (en) * 2004-03-29 2004-04-28 Glaxo Group Ltd Novel compounds
EP1737845A4 (en) * 2004-04-13 2010-07-21 Synta Pharmaceuticals Corp Disalt inhibitors of il-12 production
WO2006062481A1 (en) * 2004-12-09 2006-06-15 Biovitrum Ab New benzofuran derivatives and their use in the treatment of obesity, type ii diabetes and cns disorders .
AR054044A1 (en) * 2005-05-23 2007-05-30 Astrazeneca Ab CHROMAN AND TETRAHYDRONAFTALENE DERIVATIVES AS RECEPTOR MODULATORS 5 - HT6; INTERMEDIARIES IN THEIR PREPARATION; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPELO IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF CNS AND OBESITY DISEASES.
US7582767B2 (en) * 2005-06-17 2009-09-01 Biovitrum Ab (Publ.) Substituted sulphonamide compound and uses thereof
JP2008545008A (en) * 2005-06-30 2008-12-11 プロシディオン・リミテッド GPCR agonist
ES2513165T3 (en) 2005-10-07 2014-10-24 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol-3-kinase inhibitors
BRPI0618206A2 (en) 2005-11-03 2011-08-23 Hoffmann La Roche chromosyl arylsulfonyl as 5-ht6 inhibitors as well as pharmaceutical composition, use and process for producing them
AR058705A1 (en) 2005-12-23 2008-02-20 Astrazeneca Ab BENCIMIDAZOL COMPOUNDS AS VANILOID 1 RECEIVER INHIBITORS (VR1)
MX2008015843A (en) 2006-06-20 2009-01-09 Hoffmann La Roche Tetralin and indane derivatives and uses thereof.
CA2655524A1 (en) 2006-06-20 2007-12-27 F. Hoffman-La Roche Ag Arylsulfonamidyl tetralin derivatives and uses thereof
EP2041079A1 (en) 2006-06-20 2009-04-01 F. Hoffmann-Roche AG Arylsulfonyl naphthalene derivatives and uses thereof
TWI433839B (en) 2006-08-11 2014-04-11 Neomed Inst New benzimidazole derivatives 290
EP2508177A1 (en) 2007-12-12 2012-10-10 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
US7888662B2 (en) 2008-06-20 2011-02-15 Varian Semiconductor Equipment Associates, Inc. Ion source cleaning method and apparatus
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
JP5872027B2 (en) * 2011-05-09 2016-03-01 フォーマ ティーエム， エルエルシー． Piperidine derivatives and compositions for inhibiting nicotinamide phosphoribosyltransferase (NAMPT)
CN104725295B (en) 2013-12-20 2019-05-24 广东东阳光药业有限公司 Aromatic heterocyclic derivatives and its application on drug
AU2016276966A1 (en) 2015-06-12 2018-01-18 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of REM sleep behavior disorder
TW201720439A (en) 2015-07-15 2017-06-16 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
WO2017147328A1 (en) 2016-02-23 2017-08-31 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB947606A (en) * 1961-04-10 1964-01-22 Ici Ltd N-substituted piperazines
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
AU6391894A (en) * 1993-03-16 1994-10-11 Pfizer Inc. Naphthalene derivatives
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
DZ2376A1 (en) * 1996-12-19 2002-12-28 Smithkline Beecham Plc New sulfonamide derivatives process for their preparation and pharmaceutical compositions containing them.
GB9818916D0 (en) * 1998-08-28 1998-10-21 Smithkline Beecham Plc Use
GB9904995D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
GB9926302D0 (en) * 1999-11-05 2000-01-12 Smithkline Beecham Plc Novel compounds
WO2001032660A1 (en) * 1999-11-05 2001-05-10 Nps Allelix Corp. Compounds having 5-ht6 receptor antagonist activity
AU2001264566A1 (en) * 2000-05-05 2001-11-20 Cor Therapeutics, Inc. Heterobicyclic sulfonamides and their use as platelet adp receptor inhibitors
AU2001259707A1 (en) * 2000-06-14 2001-12-24 Warner Lambert Company 6,5-fused bicyclic heterocycles
AU2001296193B2 (en) * 2000-10-20 2006-04-27 Biovitrum Ab 2-, 3-, 4-, or 5-substituted-N1-(benzensulfonyl)indoles and their use in therapy
EP1406884A1 (en) * 2001-05-11 2004-04-14 Biovitrum Ab Arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
SK16052003A3 (en) * 2001-06-07 2004-10-05 Hoffmann La Roche New indole derivatives with 5-HT6 receptor affinity
US7144883B2 (en) * 2001-06-11 2006-12-05 Biovitrum Ab Bicyclic sulfonamide compounds

Also Published As

Publication number Publication date
RS111204A (en) 2006-12-15
IL165051A0 (en) 2005-12-18
AU2003243091A1 (en) 2004-01-06
WO2004000828A1 (en) 2003-12-31
BR0311952A (en) 2005-04-19
EP1513828A1 (en) 2005-03-16
EA200500054A1 (en) 2005-06-30
CN1662521A (en) 2005-08-31
CA2486989A1 (en) 2003-12-31
EA200600975A1 (en) 2006-10-27
EA008835B1 (en) 2007-08-31
NZ552282A (en) 2008-07-31
NZ536600A (en) 2007-08-31
NZ552283A (en) 2008-07-31
EA011581B1 (en) 2009-04-28
MXPA04012914A (en) 2005-03-31
SG156524A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
NO20050294L (en) New compounds useful in the treatment of obesity, type II diabetes and CNS disorders
NO20075781L (en) Diarylsulfone sulfonamides and their use
NO20063761L (en) Sulfonamide derivatives for the treatment of diseases
SE0403006D0 (en) New compounds
NO20044763L (en) 1- (aminoalkyl) -3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands
YU98003A (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
NO20050828L (en) indole-3-sulfur derivatives
NO20076638L (en) New 8-sulfonylamino-3-amino-substituted chroman or tetrahydronaphthalene derivatives modulating the 5HT6 receptor
NO20062983L (en) Sulfonamide derivatives for the treatment of diseases
CA2443724A1 (en) Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders
NO20055680L (en) Hexahydropyridoisoquinolines as DPP-IV inhibitors
NO20051503L (en) Pyrazolopyridines and processes for the preparation and use of the same.
NO20053792L (en) Heterocycly-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
NO20045042L (en) 7-aryl -3,9-diazabicyclo (3.1.1) non-6-ene derivatives and their use as renin. inhibitors in the treatment of hypertension, cardiovascular and kidney disease
DE60315674D1 (en) NEW IMIDAZOPYRIDINE AND ITS USE
TW200505862A (en) 2-amino-pyridine derivatives useful for the treatment of diseases
NO20052699L (en) 4 (phenylpiperazinylmethyl) benzamide derivatives and their use in the treatment of pain and gastrointestinal disorders.
NO20071222L (en) Benzamide.
BRPI0508392A (en) Materials and Methods for Treating Coagulation Disorders
NO20060687L (en) New connections
NO20060718L (en) Substituted thiophones and their use
NO20080354L (en) Benzofuranyl derivatives as 5-HT6 receptor inhibitors
NO20065835L (en) Medicines containing N-sulfamoyl-N'-arylpiperazines for the prophylaxis or treatment of obesity and related conditions
SE0303480D0 (en) Benzofuranes
NO20060969L (en) Benzoxazinone derivative sulfonamide compounds, their preparation and use as drugs

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application